Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11142136 | 0.86 | IDO1 (0.59) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL29590253 | 0.86 | IDO1 (0.59) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL8308445 | 0.84 | IDO1 (0.58) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL30908530 | 0.83 | IDO1 (0.56) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL817976 | 0.83 | IDO1 (0.56) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL1455049 | 0.82 | IDO1 (0.56) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL8558598 | 0.80 | IDO1 (0.53) | IDO1HTR2COPRM1DRD3AVPR1A | |
| SCHEMBL19911672 | 0.79 | IDO1 (0.44) | IDO1PIN1HSD11B1CA1CA2 | |
| SCHEMBL19911668 | 0.79 | IDO1 (0.44) | IDO1PIN1HSD11B1CA1CA2 | |
| SCHEMBL19911671 | 0.79 | IDO1 (0.47) | IDO1PIN1HSD11B1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | claimed |
| CN-1211322-C | Separating agent comprising polysaccharide derivative having polycyclic structure | DAICEL CHEM (JP) | 2005-07-20 | — | — | CN | claimed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| WO-2019078171-A1 | METHOD FOR CONCENTRATING OR SEPARATING POLYMER COMPOUND | 国立大学法人京都大学 | 2019-04-25 | — | — | WO | disclosed |
| US-10239846-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-03-26 | — | — | US | disclosed |
| EP-3406142-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | Celgene International II Sàrl (CH) | 2018-11-28 | — | — | EP | disclosed |
| CN-105061350-B | The sphingosine 1-phosphate receptor modulators and Chiral Synthesis of selectivity | 赛尔基因第二国际有限公司 | 2018-05-29 | — | — | CN | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-20170320839-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2017-11-09 | — | — | US | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-0979240-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 2000-02-16 | — | — | EP | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| EP-0886647-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998050420-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| WO-1997031937-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997030073-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-08-21 | — | — | WO | disclosed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320839-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | IDO1 1768/4885HTR2C 895/4885OPRM1 167/4885 |
| US-10239846-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | S1PR1, S1PR3, S1PR2 | IDO1 1768/4885HTR2C 895/4885OPRM1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.